Datto C, Hellmund R, Siddiqui MK, Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses, Open Access Rheumatology: Research and Reviews, Feb 2013:5, 1-19

Datto C, Hellmund R, Siddiqui MK

Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses

Global

Non-steroidal anti-inflammatory drugs (NSAIDs), such as non-selective NSAIDs (nsNSAIDs) or selective cyclooxygenase-2 (COX-2) inhibitors, are commonly prescribed for arthritic pain relief in patients with osteoarthritis (OA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS). Treatment guidelines for chronic NSAID therapy include the consideration for gastroprotection for those at risk of gastric ulcers (GUs) associated with the chronic NSAID therapy. The United States Food and Drug Administration has approved naproxen/esomeprazole magnesium tablets for the relief of signs and symptoms of OA, RA, and AS, and to decrease the risk of developing GUs in patients at risk of developing NSAID-associated GUs. The European Medical Association has approved this therapy for the symptomatic treatment of OA, RA, and AS in patients who are at risk of developing NSAID-associated GUs and/or duodenal ulcers, for whom treatment with lower doses of naproxen or other NSAIDs is not considered sufficient. Naproxen/esomeprazole magnesium tablets have been compared with naproxen and celecoxib for these indications in head-to-head trials. This systematic literature review and network meta-analyses of data from randomized controlled trials was performed to compare naproxen/esomeprazole magnesium tablets with a number of additional relevant comparators. For this study, an original review examined MEDLINE®, Embase®, and the Cochrane Controlled Trials Register from database start to April 14, 2009. Using the same methodology, a review update was conducted to December 21, 2009. The systematic review and network analyses showed naproxen/esomeprazole magnesium tablets have an improved upper gastrointestinal tolerability profile (dyspepsia and gastric or gastroduodenal ulcers) over several active comparators (naproxen, ibuprofen, diclofenac, ketoprofen, etoricoxib, and fixed-dose diclofenac sodium plus misoprostol), and are equally effective as all active comparators in treating arthritic symptoms in patients with OA, RA, and AS. Naproxen/esomeprazole magnesium tablets are therefore a valuable option for treating arthritic symptoms in eligible patients with OA, RA, and AS

non-steroidal anti-inflammatory drug, proton pump inhibitor, upper gastrointestinal tolerability, arthritis

OBJECTIVES: To assess clinical effectiveness of cognitive behavioural therapy (CBT) in patients with multiple sclerosis (MS) fatigue. METHODS: Embase® and Cochrane databases were searched up to June 2012 to identify randomised controlled trials published in English evaluating effect of CBT (disseminated by any mode) in patients with MS fatigue. Eligibility of trials was assessed by two reviewers with any discrepancy reconciled by a third, independent reviewer. To compare CBT with other therapies, random-effect meta-analysis was conducted using Stata® (v11.1) on change from baseline to endpoint in fatigue score. RESULTS: Four studies of 107 retrieved citations met pre-defined inclusion criteria. Two studies compared CBT to no therapy and one study each compared CBT to relaxation therapy (RT) and supportive-expressive group therapy (SEGP). All studies were well conducted and no significant differences were observed between treatment groups for demographic characteristics. Weighted mean difference (WMD) demonstrated statistically significant reduction for change in fatigue score at 2 months from baseline with CBT versus no therapy (-7.04; p<0.001). When CBT was compared to RT, WMD was -4.29 (p<0.001) at 2 months, -2.74 (p=0.013) at 5 months, and -2.74 (p=0.027) at 8 months indicating that CBT group improved significantly on fatigue than RT group and this improvement was sustained over a period of time. Further, when CBT was assessed against SEGP, WMD was -12.2 (p=0.024) at 4 months, indicating that CBT (individualised therapy) demonstrated significantly better reduction in fatigue compared to SEGP (group therapy). CONCLUSIONS: Overall results demonstrated that CBT was significantly superior in alleviating fatigue compared to no therapy, RT, and SEGP. CBT appears to be promising, acceptable and clinically beneficial approach that could potentially benefit patients with MS fatigue in future. Thus, further research is warranted to determine which aspects of CBT are most effective and the optimal delivery of CBT for MS fatigue.

Kohli IS, Kataria A, Singla S, Kaushik P, Jindal R, Aggarwal A

Effect of Cognitive Behavioural Therapy on Muiltiple Sclerosis Fatigue: A Systematic Review of Randomised Control Trials

METHODS: Embase® and Cochrane databases were searched up to June 2012 to identify randomised controlled trials published in English evaluating effect of CBT (disseminated by any mode) in patients with MS fatigue. Eligibility of trials was assessed by two reviewers with any discrepancy reconciled by a third, independent reviewer. To compare CBT with other therapies, random-effect meta-analysis was conducted using Stata® (v11.1) on change from baseline to endpoint in fatigue score.

Objective To evaluate the cost-utility of adding tiotropium to usual care versus usual care alone for patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the UK and Belgium. Methods A four-state Markov model was developed with three disease severity states (moderate, severe, very severe) and death. Severity was based on post-bronchodilator FEV1 and transitions were based on outcomes of the Understanding Potential Long Term Impacts on Function with Tiotropium (UPLIFT®) trial. Utilities were derived from EQ-5D scores for a subset of UPLIFT® patients. UK costs were evaluated separately for England (E), and for Scotland, Wales and Northern Ireland (SWNI). Belgian (B) costs were obtained from local sources. Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA). Results Adding tiotropium to usual care resulted in an incremental cost per patient of €969 (B), £796 (E), and £812 (SWNI), and incremental QALYs of 0.052 (B), and 0.051 (E, SWNI). The four-year incremental cost-effectiveness ratios (ICER) were €18,617 (B), £15,567 (E) and £15,890 (SWNI) per QALY. Probability of tiotropium being cost-effective at £30,000 (€50,000) per QALY gained was greater than 60%. Conclusions At willingness to pay thresholds of £(€) 30,000 per QALY gained, adding tiotropium to usual care is cost-effective

Hettle, R., Wouters, H., Ayres, J., Gani, R., Kelly, S., Lion, M., Decramer, M.

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium

A four-state Markov model was developed with three disease severity states (moderate, severe, very severe) and death. Severity was based on post-bronchodilator FEV1 and transitions were based on outcomes of the Understanding Potential Long Term Impacts on Function with Tiotropium (UPLIFT®) trial. Utilities were derived from EQ-5D scores for a subset of UPLIFT® patients. UK costs were evaluated separately for England (E), and for Scotland, Wales and Northern Ireland (SWNI). Belgian (B) costs were obtained from local sources. Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).

UK, Belgium

COPD, respiratory

Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis, AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV, [ahead of print]

Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM.

The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis.

Poor adherence to antiretroviral therapies (ARTs) in human immunodeficiency virus (HIV)-infected patients increases the risk of incomplete viral suppression, development of viral resistance, progression to acquired immune deficiency syndrome and death. This study assesses the impact of specific treatment-related adverse events (AEs) on adherence to ART in the adult HIV patient population. A systematic review of studies involving adult HIV-infected patients aged ≥ 16 years that reported an odds ratio (OR) for factors affecting adherence to ART was conducted through a search of the EMBASE® and Medline® databases. Database searches were complemented with a search of titles in the bibliographies of review papers. Studies conducted in populations limited to a particular demographic characteristic or behavioural risk were excluded. To qualify for inclusion into a meta-analysis, treatment-related AEs had to be defined similarly across studies. Also, multiple ORs from the same study were included where study sub-groups were distinct. Random effects models were used to pool ORs. In total, 19 studies and 18 ART-related AEs were included in meta-analyses. Adherence to ART was significantly lower in patients with non-specific AEs than in patients who did not experience AEs [OR = 0.623; 95% confidence interval (CI): 0.465-0.834]. Patients with specific AEs such as fatigue (OR = 0.631; 95% CI: 0.433-0.918), confusion (OR = 0.349; 95% CI: 0.184-0.661), taste disturbances (OR = 0.485; 95% CI: 0.303-0.775) and nausea (OR = 0.574; 95% CI: 0.427-0.772) were significantly less likely to adhere to ART compared to patients without these AEs. Knowledge of specific treatment-related AEs may allow for targeted management of these events and a careful consideration of well-tolerated treatment regimens to improve ART adherence and clinical outcomes.

HIV, adherence, systematic review, Merck

Bachman, E, Kumar, J., Zaidi, Q.

Bachman, E, Kumar, J., Zaidi, Q. The US orphan drug landscape: before and after EU orphan drug legislation of 2000, poster presentation PHP94, ISPOR 17th Annual International Meeting
Washington, D.C., USA, June, 2012

The US orphan drug landscape: before and after EU orphan drug legislation of 2000

US healthcare reforms, obamacare, US health policy

Bachman, E., McAlister, A. The intrinsic value of extended release drugs, poster presentation PIH 28, ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012,

Bachman, E., McAlister, A.

The intrinsic value of extended release drugs

mode of delivery, product value, value proposition

Srivastava, K., Arora, A, Kataria, A., Cappalleri, J., Sadosky, A. Peterson, A. The impact of reducing dosing frequency of oral therapies on adherence, compliance and cost for acute and chronic illnesses: a meta-analysis, poster presentation PIH31, ISPOR 17th Annual International Meeting Washington, D.C., USA, June, 2012,

Srivastava, K., Arora, A, Kataria, A., Cappalleri, J., Sadosky, A. Peterson, A.

The impact of reducing dosing frequency of oral therapies on adherence, compliance and cost for acute and chronic illnesses: a meta-analysis

data analytics, meta-analysis

Maiese, EM, Al-Addak, I., McCann, E., Patel, S., Gadkari, A,. Prajapati, G., The impact of HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review of meta-analysis, poster presentation PIN45, ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Maiese, EM, Al-Addak, I., McCann, E., Patel, S., Gadkari, A,. Prajapati, G.,

The impact of HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review of meta-analysis

HIV, sexually transmitted disease, STD, virus

Goldenbrerg, D., Bachman, E., The future of alternative pricing/risk sharing agreements in in the United States, poster presentation PHP 98, ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Goldenbrerg, D., Bachman, E.,

The future of alternative pricing/risk sharing agreements in in the United States, poster presentation

Risk sharing, US healthcare reform, policy, healthcare reform, Obama.

Pietri, G. Kennedy, K, Bouchard, J, Goldhammer, M., The cost of hypoglycemic events associated with diabetes: a retrospective claims database study, poster presentation PDB 37, ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Pietri, G. Kennedy, K, Bouchard, J, Goldhammer, M.,

The cost of hypoglycemic events associated with diabetes: a retrospective claims database study

Diabetes, Diabetes Melitus, data nalytics, retrospective database analysis

Kennedy, K, Wang, M, Goldhammer, M, Bouchard, The cost of complicaitons associated with diabetes: a retrospective claims database study, poster presentation ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Kennedy, K, Wang, M, Goldhammer, M, Bouchard, J,

The cost of complicaitons associated with diabetes: a retrospective claims database study

diabetes, diabetes melitus, data analytics, database

Alexopoulos, ST, Deniz, B, Walker, A, Arnold, R, Bates, D Economic evaluation of Natalizumab versus Fingolimod for the treatment of relapsing-remitting multiple sclerosis in Sweden, poster presentation, ISPOR 17th Annual International Meeting, Washington, D.C., USA June, 2012

Alexopoulos, ST, Deniz, B, Walker, A, Arnold, R, Bates, D

Economic evaluation of Natalizumab versus Fingolimod for the treatment of relapsing-remitting multiple sclerosis in Sweden

MS, Multiple Sclerosis

Ismaila, A, Posnett, J, Walker, A, Sayani, A, Laroche, B, Nickel, J, Robson, R, Su, Z. Cost-effectiveness of a new fixed-dose combination of Dutasteride and Tamsulosin for the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada, ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Ismaila, A, Posnett, J, Walker, A, Sayani, A, Laroche, B, Nickel, J, Robson, R, Su, Z.

Cost-effectiveness of a new fixed-dose combination of Dutasteride and Tamsulosin for the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada

Canada

Prostate, hyperplasia, BPH, BEP benign prostatic hypertrophy

Rebeira, M, Murphy, J, Pietri, G. Goldberg, J, 'Cost-effectiveness analysis of Plerixafor for stem cell mobilization for poor mobilizers in Canada', poster presentation ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Rebeira, M, Murphy, J, Pietri, G. Goldberg, J,

Cost-effectiveness analysis of Plerixafor for stem cell mobilization for poor mobilizers in Canada

Canada

stem cells, cost utility, cost studies, cost study

Ismaila A, Posnett J, Walker A, Sayani A, Robson R, Su Z, 'Budget impact analysis of adding a new fixed-dose combination therapy of Dutasteride and Tamsulosin to the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada', poster presentation ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Ismaila A, Posnett J, Walker A, Sayani A, Robson R, Su Z

Budget impact analysis of adding a new fixed-dose combination therapy of Dutasteride and Tamsulosin to the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada

Prostate, prostate cancer, reproduction, budget impact model

Walker A, Deniz B, Alexopoulos T, Arnold R, Bates D A risk-benefit analysis of natalizumab across PML risk sub-groups in patients with relapsing-remitting multiple sclerosis, ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012

Walker A, Deniz B, Alexopoulos T, Arnold R, Bates D

A risk-benefit analysis of natalizumab across PML risk sub-groups in patients with relapsing-remitting multiple sclerosis

MS, Multiple Sclerosis, Scleroid,

Zhang Y, Plested M, Hettle R, Orsini L, A systematic review of health state utilities in patients with advanced hepatocellular carcinoma, poster presentation ISPOR 17th Annual International Meeting, Washington DC, June 2012

Zhang Y, Plested M, Hettle R, HERON UK, Orsini L, Bristol Myers Squibb

A systematic review of health state utilities in patients with advanced hepatocellular carcinoma

Global, International

cancer, review, carcinoma

McCann E, Al-Dakkak I, McAlister A, Patel S, HERON, Luton UK, Assessing Inconsistencies in adherence research: a systematic review, presented at ISPOR 17th Annual International Meeting, Washington, D.C., USA, June, 2012, PIH30

McCann E, Al-Dakkak I, McAlister A, Patel S,

Assessing inconsistencies in adherence research: a systematic review

Global, International

adherence metrics, adhere

Budhia, S., Mikyas, Y., Tang, M., Badamgarav, E. (2012) Osteoporotic Fractures: A Systematic Review of US Healthcare Costs and Resource Utilization. Pharmacoeconomics 30 (2): 1-24.

Budhia, S., Mikyas, Y., Tang, M., Badamgarav, E.

Osteoporotic Fractures: A Systematic Review of US Healthcare Costs and Resource Utilization. Pharmacoeconomis 30 (2): 1-24.

health policy, USA, healthcare reforms

Al-Dakkak, I., Patel, S., Jen, MH., von Maltzahn, R. R... You aware how useful it is? The value of correlation coefficients in meta-analysis. Poster presentation PRM46: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011.

Al-Dakkak, I., Patel, S., Jen, MH., von Maltzahn, R. R...

You aware how useful it is? The value of correlation coefficients in meta-analysis. Poster presentation PRM46: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011.

methodology, meta-analysis, evidence review